TD Cowen Maintains Buy on TransMedics Group, Lowers Price Target to $120
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
TD Cowen analyst Joshua Jennings maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $190 to $120.
TD Cowen analyst Joshua Jennings maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $190 to $120.